Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures

X
Trial Profile

An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Study of E2007 (Perampanel) as an Adjunctive Therapy in Patients With Refractory Partial Seizures

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 09 Jul 2020 Results (N=858), post hoc analysis of open-label extension (OLEx) studies assessing the ong-term efficacy and safety in patients with focal to bilateral tonic clonic seizures (FBTCS) or generalized tonic clonic seizures, published in the Epilepsia
    • 28 Apr 2017 Results of a pooled analysis assessing the long-term efficacy and safety of adjunctive perampanel in patients from four phase II/III open-label extension studies (207, 307, 335 and 332), presented at the 69th Annual Meeting of the American Academy of Neurology
    • 13 Apr 2017 According to an Eisai Inc media release, results of pooled analysis assessing long-term efficacy and safety of adjunctive perampanel from four open-label extension studies (207, 307, 335 and 332) will be presented at the American Academy of Neurology (AAN) Annual Meeting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top